The applications of phase change materials (PCMs) in some practical circumstances are currently limited due to the constant strong rigidity, poor thermal conductivity, and low photoabsorption property. Therefore, the design of flexibility-enhanced, highly efficient PCMs is greatly desirable and challenging. In this work, novel PCM composites (CPmG-x) with stable forms and thermally induced flexibility were successfully prepared by grafting the comblike poly(hexadecyl acrylate) polymer (PA16, phase change working substance) onto a cellulose support by atom transfer radical polymerization (ATRP). Modified graphene (GN16) was incorporated into the synthesized material to enhance its enthalpy, thermal conductivity, and physical strength. The prepared CPmG-x composites exhibit excellent softness and flexibility after phase transition of PA16. The addition of GN16 increases the thermal conductivity and enthalpy of CPmG-x materials to 1.32 W m^-1 K^-1 (9 wt % GN16) and 103 J g^-1 (5 wt % GN16), respectively. Assessments of the solar-to-thermal energy conversion and storage efficiencies indicate that CPmG-x composites possess great potential for use in thermal energy management applications and solar energy collection systems.

01 Apr 2015·Journal of Immunological MethodsQ4 · MEDICINE

Comparison of cell-based and non-cell-based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteins

Q4 · MEDICINE

Article

Author: Civoli, Francesca ; Kaliyaperumal, Arunan ; Barger, Troy ; Zhuang, Yao ; Hu, Jenny ; Han, Hong ; Wala, Iwona ; Gupta, Shalini ; Nagatani, Janice

Anti-drug neutralizing antibodies (NAbs) formed due to unwanted immunogenicity of a therapeutic protein point towards a mature immune response. NAb detection is important in interpreting the therapeutic's efficacy and safety in vivo. In vitro cell-based NAb assays provide a physiological system for NAb detection, however are complex assays. Non-cell-based competitive ligand binding (CLB) approaches are also employed for NAb detection. Instead of cells, CLB assays use soluble receptor and conjugated reagents and are easier to perform, however have reduced physiological relevance. The aim of this study was to compare the performance of CLB assays to established cell-based assays to determine the former's ability to detect clinically relevant NAbs towards therapeutics that (i) acted as an agonist or (ii) acted as antagonists by binding to a target receptor. We performed a head-to-head comparison of the performance of cell-based and CLB NAb assays for erythropoietin (EPO) and two anti-receptor monoclonal antibodies (AMG-X and AMG 317). Clinically relevant NAb-positive samples identified previously by a cell-based assay were assessed in the corresponding CLB format(s). A panel of 12 engineered fully human anti-EPO monoclonal antibodies (MAbs) was tested in both EPO NAb assay formats. Our results showed that the CLB format was (i) capable of detecting human anti-EPO MAbs of differing neutralizing capabilities and affinities and (ii) provided similar results as the cell-based assay for detecting NAbs in patient samples. The cell-based and CLB assays also behaved comparably in detecting NAbs in clinical samples for AMG-X. In the case of anti-AMG 317 NAbs, the CLB format failed to detect NAbs in more than 50% of the tested samples. We conclude that assay sensitivity, drug tolerance and the selected assay matrix played an important role in the inability of AMG 317 CLB assays to detect clinically relevant NAbs.

100 Deals associated with IGEG-X

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Discovery	GB	Epsilogen Ltd.Startup	13 Mar 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

IGEG-X

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation